Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: A sequential approach

International Journal of Radiation Oncology Biology Physics

Volumn 67, Issue 1, 2007, Pages 110-116

  Lupe, Krystine ^a   Kwon, Janice ^a   D'Souza, David ^a   Gawlik, Christine ^a   Stitt, Larry ^a   Whiston, Frances ^a   Nascu, Patricia ^a   Wong, Eugene ^a   Carey, Mark S ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adjuvant therapy; Endometrial cancer; Paclitaxel and carboplatin; Radiation; Toxicity

Indexed keywords

ONCOLOGY; PATIENT TREATMENT; RADIATION; RADIOTHERAPY; TOXICITY;

ADJUVANT THERAPY; ENDOMETRIAL CANCER; PACLITAXEL AND CARBOPLATIN;

CHEMOTHERAPY;

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG HYPERSENSITIVITY; ENDOMETRIUM CANCER; EVALUATION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCYTOPENIA; PRIORITY JOURNAL; PROCTITIS; RADIATION FIELD; SIDE EFFECT; SURVIVAL RATE; URINARY TRACT DISEASE; VOMITING;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; HYSTERECTOMY; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY DOSAGE;

EID: 33845613561     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.08.006     Document Type: Article

References (31)

1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2003 (2006)
2. National Cancer Institute of Canada. Canadian Cancer Statistics 2006.
3. Nelson G., Randall M.E., Sutton G., Moore D., Hurteau J., and Look K. FIGO Stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol 75 (1999) 211-214
4. McMeekin D.S., Lashbrook D., Gold M., Johnson G., Walker J.L., and Mannel R. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol 81 (2001) 273-278
5. Greven K.M., Lanciano R.M., Corn B., Case D., and Randall M.E. Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 71 (1993) 3697-3702
6. Greven K.M., Curran Jr. W.J., Whittington R., et al. Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. Int J Radiat Oncol Biol Phys 17 (1989) 35-39
7. Randall M.E., Filiaci V.L., Muss H., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecol Oncol Group Study. J Clin Oncol 24 (2006) 36-44
8. Mundt A.J., McBride R., Rotmensch J., Waggoner S.E., Yamada S.D., and Connell P.P. Significant pelvic recurrence in high-risk pathologic stage I-IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 1145-1153
9. Aoki Y., Kase H., Watanabe M., Sato T., Kurata H., and Tanaka K. Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol Oncol 83 (2001) 1-5
10. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecol Oncol Group study. Gynecol Oncol 92 (2004) 744-751
11. Creutzberg C.L., van Putten W.L., Warlam-Rodenhuis C.C., et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22 (2004) 1234-1241
12. Aalders J., Abeler V., Kolstad P., and Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56 (1980) 419-427
13. Hoskins P.J., Swenerton K.D., Pike J.A., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 19 (2001) 4048-4053
14. Dimopoulos M.A., Papadimitriou C.A., Georgoulias V., et al. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. Gynecol Oncol 78 (2000) 52-57
15. Ball H.G., Blessing J.A., Lentz S.S., and Mutch D.G. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecol Oncol Group study. Gynecol Oncol 62 (1996) 278-281
16. Tonkin K.S., Levin L., and Powe J. Neither toxicity nor dose intensity of carboplatin is affected by glomerular filtration rate versus body surface area dose calculation in gynecologic malignancy. Int J Gynecol Cancer 4 (1994) 315-319
17. National Cancer Institute. Common Terminology Criteria for Adverse Events Version 3 (2006)
18. Wong E., D'Souza D.P., Chen J.Z., et al. Intensity-modulated arc therapy for treatment of high-risk endometrial malignancies. Int J Radiat Oncol Biol Phys 61 (2005) 830-841
19. Radiation Therapy Oncology Group. Cooperative Group Common Toxicity Criteria 2006.
20. Bruzzone M., Miglietta L., Franzone P., Gadducci A., and Boccardo F. Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients. Gynecol Oncol 93 (2004) 345-352
21. Duska L.R., Berkowitz R., Matulonis U., et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol 96 (2005) 198-203
22. Soper J.T., Reisinger S.A., Ashbury R., Jones E., and Clarke-Pearson D.L. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecol Oncol Group trial. Gynecol Oncol 95 (2004) 95-100
23. Greven K.M., Winter K., Underhill K., Fontenesci J., Cooper J., and Burke T. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int J Radiat Oncol Biol Phys 59 (2004) 168-173
24. Frigerio L., Mangili G., Aletti G., et al. Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol 81 (2001) 53-57
25. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecol Oncol Group Study. J Clin Oncol 22 (2004) 2159-2166
26. Akram T., Maseelall P., and Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 192 (2005) 1365-1367
27. Scudder S.A., Liu P.Y., Wilczynski S.P., et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol 96 (2005) 610-615
28. Humber C., Tierney J., Symonds P., et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev (2005) Oct 19:CD003915
29. Carey M.S., Gawlik C., Fung-Kee-Fung M., Chambers A., and Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 101 (2006) 158-167
30. Vaidya A.P., Littell R., Krasner C., and Duska L.R. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer 16 Suppl 1 (2006) 267-272
31. Greven K., Winter K., Underhill K., Fontenesci J., Cooper J., and Burke T. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 103 (2006) 155-159